Early Activation of Hemostasis during Cardiopulmonary Bypass: Evidence for Thrombin Mediated Hyperfibrinolysis

Summary

In 14 consecutive patients undergoing cardiopulmonary bypass for coronary bypass surgery the time course of coagulation and fibrinolysis markers were measured, e.g. plasma levels of thrombin-antithrombin III (TAT) complexes, cross-linked fibrin degradation products (X1FDP) and plasmin-α₂-antiplasmin complexes (PAP). TAT levels exceeded the 90% baseline percentile already during CPB (after opening of aortic clamp) in 10 patients, whereas PAP and X1FDP exceeded their 90% percentile in only one patient at this time. Concerning fibrinolysis markers PAP and X1FDP the majority of patients showed elevations higher than their 90% baseline percentile only 1 h postoperation. Correlation analysis revealed significant dependencies between TAT levels during and at the end of CPB and PAP levels 1 h postoperation (R = 0.55 and R = 0.56 respectively). Furthermore, 1 h postoperation X1FDP levels were significantly correlated with both TAT and PAP. Peak X1FDP levels at the same time correlated with blood loss via thoracic drains (R = 0.56). Thus, we suggest that hyperfibrinolysis in patients undergoing CPB is at least partly due to hypercoagulation. Clinically, this may implicate that intensified anticoagulation could prevent hyperfibrinolysis and reduce postoperative blood loss.

• References

• 1 McKenzie FN, Dhall DP, Arfors KE, Nordlund S, Matheson NA. Blood platelet behavior during and after open-heart surgery. Br Med J 1969; 2: 795-798
• 2 McKenna R, Bachmann F, Whittaker B, Gilson JR, Weinberg M. The hemostatic mechanism after open-heart surgery. II. Frequency of abnormal platelet functions during and after extracorporeal circulation. J Thorac Cardiovasc Surg 1975; 70: 298-308
• 3 Harker LA, Malpass TW, Branson HE, Hessel EA, Slichter SJ. Mechanism of abnormal bleeding in patient undergoing cardiopulmonary bypass: Acquired transient platelet dysfunction associated with selective alpha-granule release. Blood 1980; 56: 824-834
• 4 Knöbl P, Zilla P, Fasol R, Müller M, Vukovich T. The protein C system in patients undergoing cardiopulmonary bypass. J Thorac Cardiovasc Surg 1987; 94: 600-605
• 5 Havel M, Teufelsbauer H, Knöbl P, Dalmatiner R, Jaksch P, Zwölfer W, Müller M, Vukovich T. The effect of intraoperative aprotinin administration on postoperative bleeding in patients undergoing cardiopulmonary bypass surgery. J Thorac Cardiovasc Surg 1991; 101: 968-972
• 6 Kalter RD, Saul CM, Wetstein L, Soriano C, Reiss RF. Cardiopulmonary bypass: associated hemostatic abnormalities. J Thorac Cardiovasc Surg 1979; 77: 427-435
• 7 Mammen EF, Koets MH, Washington BC, Wolk L, Brown JM, Burdick M, Selik NR, Wilson RF. Hemostasis changes during cardiopulmonary bypass surgery. Semin Thromb Hemostas 1985; 11: 281-292
• 8 Soloway HB, Cornett BM, Donahoo JV, Cox SP. Differentiation of bleeding diathesis which occur following protamine correction of heparin anticoagulation. Am J Clin Pathol 1973; 59: 188-191
• 9 Shanberge JN, Murato M, Quattrociocchi T, Neste L. Heparin-protamine complexes in the production of heparin rebound and other complications of extracorporeal bypass procedures. Am J Clin Pathol 1987; 87: 210-217
• 10 Stibbe J, Kluft C, Brommer EJP, Gomes M, deJong D, Nauta J. Enhanced fibrinolytic activity during cardiopulmonary bypass in open-heart surgery in man is caused by extrinsic (tissue-type) plasminogen activator. Eur J Clin Invest 1984; 14: 375-382
• 11 Gram J, Janetzko T, Jesperson J, Bruhn HD. Enhanced effective fibrinolysis following the neutralization of heparin in open heart surgery increases the risk of post-surgical bleeding. Thromb Haemostas 1990; 63: 241-245
• 12 Dechavanne M, French M, Pages J, French P, Boukerche H, Byron PA, McGregor JL. Significant reduction in the binding of a monoclonal antibody (LYP18) directed against the IIb/IIIa glycoprotein complex to platelets of patients having undergone extracorporeal circulation. Thromb Haemostas 1987; 57: 106-109
• 13 Wenger RK, Lukasiewicz H, Mikuta BS, Niewiarowski S, Edmunds Jr HL. Loss of platelet fibrinogen receptors during clinical cardiopulmonary bypass. J Thorac Cardiovasc Surg 1989; 97: 235-243
• 14 Salm TJV, Ansell JE, Okike ON, Marsicano TH, Lew R, Stephenson WP, Rooney K. The role of epsilon-aminocaproic acid in reducing bleeding after cardiac operation: A double-blind randomized study. J Thorac Cardiovasc Surg 1988; 95: 538-540
• 15 Royston D, Bidstrup BP, Tayler KM, Sapsford RN. Effect of aprotinin on need for blood transfusion after repeat open-heart surgery. Lancet 1987; 2: 1289-1291
• 16 Davies GC, Sobel M, Salzman EW. Elevated plasma fibrinopeptide A and thromboxane A2 levels during cardiopulmonary bypass. Circulation 1980; 61: 808-814
• 17 Gebhard W, Tschesche H, Fritz H. Biochemistry of aprotinin and aprotinin-like enzymes. In: Protease Inhibitors. Barett A, Salvesen G. eds Elsevier, Amsterdam: 1986. pp 375-388
• 18 Ratnoff OD. Epsilon-aminocaproic acid – a dangerous weapon. N Engl J Med 1969; 180: 1124
• 19 Böhrer H, Fleischer F, Lang J, Vahl C. Early formation of thrombi on pulmonary artery catheters in cardiac surgical patients receiving high-dose aprotinin. J Cardiothorac Anesth 1990; 4: 222-225
• 20 Youngberg JA. Aprotinin and thrombus formation on pulmonary artery catheters – Editorial. J Cardiothorac Anesth 1990; 4: 155-158